The gene therapy regimen seems to be working wonders, including restoring nearly all hearing to a seven-year-old patient ...

In a new experimental study, scientists from Juntendo University in collaboration with researchers from the University of Tokyo have developed an adeno-associated virus (AAV) vector-mediated ...

Adeno Associated Virus Vector Manufacturing Market Size, Share & Trends Analysis Report By Scale Of Operations (Clinical, Commercial), By Method, By Application, By Therapeutic Area, By Region ...

Adeno-Associated Virus Vectors in Gene Therapy Companies are Biomarin Pharmaceutical, Sarepta Therapeutics, Roche (Spark Therapeutics), Sangamo, Pfizer, NightstaRx, Freeline Therapeutics, Horama S ...

The Global Adeno Associated Virus Vector Manufacturing Market was valued USD 759 Million in 2023 and projected to reach USD 3,700.6 Million by 2030, growing at a CAGR of 21.9% during the forecast ...

The global adeno associated virus vector manufacturing market size is expected to reach USD 3.95 billion by 2030, registering a CAGR of 22.5% over the forecast period.

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

The biotech will add a pivotal Phase III cohort to its ongoing Phase I/II trial evaluating ATSN-201 in X-linked retinoschisis ...

Adeno-associated virus is an attractive vector for gene therapy as it is non-pathogenic and integrates into a specific site in the human genome. In the December 11 Early Edition of the Proceedings of ...

The global adeno associated virus vector manufacturing market size is expected to reach USD 3.95 billion by 2030, registering a CAGR of 22.5% over the forecast period. This growth is attributed to ...

The Adeno Associated Virus Vector Manufacturing market is characterized by a fragmented structure, with many competitors holding a significant share of the market. List of major players included in ...